New drug cocktail shows promise for Tough-to-Treat lymphoma

NCT ID NCT05800366

Recruiting now Disease control Sponsor: Jennifer Crombie, MD Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding two newer drugs, glofitamab and polatuzumab, to standard chemotherapy (R-CHP) can improve outcomes for people with high-risk diffuse large B-cell lymphoma. About 41 adults with untreated CD20-positive lymphoma will receive the combination. The main goal is to see how many patients achieve complete remission, while also monitoring side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-GRADE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma high grade B-cell lymphoma lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LYMPHOMA LYMPHOMA, LARGE B-CELL, DIFFUSE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
University of Miami Sylvester Cancer Center
RECRUITING

Miami, Florida, 33136, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.